This symposium will provide a rapid review of recent updates from the scientific literature from 2015 to 2016 in addiction medicine. We will begin with articles related to the neurobiology of addiction and progress to epidemiology, pharmacology, intoxication and withdrawal syndromes, screening and diagnosis, mutual help, special topics including harm reduction, special populations including the criminal justice population, and end with an overview of addiction treatments including pharmacologic and behavioral interventions. We will review key articles from the past twelve months, with a focus on those published in high impact factor journals and studies with particularly noteworthy findings. We will structure this as a "rapid-fire journal club" and will encourage audience participation. We will also discuss implications of research findings and possible relevance to clinical practice. The goal of this symposium is to provide the learner with a concise, structured, and evidence-based summary of the most recent scientific evidence in the field using The ASAM Principles of Addiction Medicine, fifth edition as a guide.
Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.
Joshua D. Lee
MD, MSc, FASAM
Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.